Automatic prior art searching


In the intellectual property field two task s are of high relevance: prior art search ing and patent classification. Prior art search is fundamental for many strategic issues such as patent granting, freedom to operate and opposition . Accurate classification of patent documents according to the IPC code system is vital for the interoperability between different patent offices and for the prior art search task involved in a patent application procedure. In this paper, we report our experiments with prior art search ing and patent classification in the context of CLEF - IP ’10 evaluation track. In the Prior Art Candidates search task, we strongly improved our last year’s model based on our experiments on training data (MAP 0.22) , but official results , alas, w ere far from the expected one s (MAP 0.14) .

According to EPO, i t is estimated that 80% of the knowledge is found in patent documents. Due to its importance as source of knowledge and to the delay in patent analysis caused the growth of applications, new areas of knowledge and size of patent databases, new tools to automate patent search ing and classification process es have become a hot topic in the last decades . As example, we can cite the challenges CLEF 2009, TREC - CHEM 2009 - 2010 and the workshops SIGIR 20 00, ACL 2003 and NTCIR 3 - 8 which all have tasks dedicated to patent retrieval. In that context, the CLEF - IP 2010 evaluation track proposes two tasks for automation of prior art search ing and of patent classification.
Global pharma companies are reluctant to introduce the latest cancer drugs because they fear patent infringement allegations from India. The stalling of clinical trials since January 2013 has also made access to advanced cancer drugs impossible in the country, said Dr. BS Ajaikumar, chairman, Healthcare Global Enterprises (HCG) which is India’s largest network chain of 27 dedicated cancer care centres in the country.

The hostile response from global pharma majors to boycott new cancer medicines into India ensues Novartis’ Gleevac drug which lost its patent protection here.  This has turned painful for the scores of cancer patients in the country as they do not have access to the advanced targeted therapies. In this regard, HCG has made a representation to the new government and its health minister Dr. Harsh Vardhan to take a look into the issue and provide remedial measures at the earliest.

It was at the conference of the Association of Surgical Oncologists in the US where global drug majors told the HCG chief that India was no longer on their radar for new cancer drugs. They were wary of the Union government as it did not comprehend innovation nor valued the intellectual property rights but were more keen to protect its generic drug manufacturers. Unless there is a relook by the government, only then India would be reconsidered, said Dr. Ajai during an interaction with the media.

http://www.pharmabiz.com/NewsDetails.aspx?aid=82842&sid=2
Collegium Pharmaceutical, a specialty pharmaceutical company, has announced that U.S. Patent No. 8,758,813 has been issued by the U.S. Patent and Trademark Office (USPTO).

The patent relates to Collegium's Oxycodone DETERx formulation and contains claims that cover the Company's lead product, an abuse-deterrent, extended-release oxycodone product utilizing its proprietary DETERx technology.

Collegium currently has six U.S. patents that are Orange Book listable. All issued patents provide protection until 2025. Outside of the U.S., Collegium has three patents in Japan, Australia and Canada.

Oxycodone DETERx is currently in Phase 3 clinical development and topline data is anticipated in Q3 2014. The product has been designated Fast Track Status by the FDA.

http://itsoftware.pharmaceutical-business-review.com/news/collegium-gets-us-patent-covering-oxycodone-deterx-030714-4309528
top